Treatment of Vascular Cognitive Impairment

Area of Science:

• Neurology
• Geriatrics
• Public Health

Background:

• Cerebrovascular disease (CVD) is a primary driver of cognitive dysfunction and dementia.
• Vascular cognitive impairment (VCI) encompasses the full spectrum of cognitive decline linked to CVD.
• Effective management of vascular risk factors is crucial for VCI prevention and treatment.

Purpose of the Study:

• To review current understanding and treatment options for VCI.
• To highlight the importance of early intervention and risk factor management.
• To discuss specific considerations for conditions like CADASIL, CAA, and SWMD.

Main Methods:

• Review of existing literature on VCI pathophysiology and treatment.
• Analysis of clinical trial data for pharmacological interventions.
• Evaluation of evidence for lifestyle and preventative strategies.

Main Results:

• Acetylcholinesterase inhibitors and memantine show modest cognitive benefits in vascular dementia but inconsistent functional improvements.
• Evidence supporting therapies like aspirin, calcium channel blockers, and vitamin supplements for VCI is limited.
• Primary prevention strategies (hypertension control, diet, exercise, smoking cessation) may reduce cognitive decline risk, but direct VCI improvement evidence is scarce.

Conclusions:

• Current treatment options for VCI are limited, with modest benefits from some pharmacological agents.
• Early intervention and aggressive management of vascular risk factors are paramount for VCI.
• Further research is needed into the pathophysiology and targeted treatments for specific VCI subtypes like CADASIL, CAA, and SWMD.